Supplementary Table S2: Demographic and health information of prostate cancer patients.

		Non-Treated (n=41)	Treated with Abiraterone Only (n=16)	Treated with Enzalutamide Only (n=13)
Race	*Caucasian*	30 (73.2%)	9 (56.3%)	11 (84.6%)
	African American	10 (24.4%)	7 (43.7%)	2 (15.4%)
	Unknown	1 (2.4%)	0 (0%)	0 (0%)
Age	*18-64*	18 (43.9%)	3 (18.8%)	3 (23.1%)
	≥65	23 (56.1%)	13 (81.2%)	10 (76.9%)
Metastasis	*None*	16 (39.0%)	1 (6.3%)	0 (0%)
	Bone	23 (56.1%)	14 (87.4%)	11 (84.6%)
	Other Sites	2 (4.9%)	1 (6.3%)	2 (15.4%)
Gleason Score	*<4*	0 (0%)	0 (0%)	0 (0%)
	>4	38 (92.7%)	14 (87.5%)	13 (100%)
	Unknown	3 (7.3%)	2 (12.5%)	0 (0%)
PSA Level Post-Therapy (ng/mL)	*<4*	24 (58.5%)	7 (43.7%)	5 (38.5%)
	>4	17 (41.5%)	9 (56.3%)	8 (61.5%)
	Unknown	0 (0%)	0 (0%)	0 (0%)
Family History of Cancer	*No*	12 (29.3%)	5 (31.3%)	3 (23.1%)
	Yes	25 (61%)	10 (62.4%)	8 (61.5%)
	Unknown	4 (9.7%)	1 (6.3%)	2 (15.4%)
Prostatectomy	*No*	0 (0%)	8 (50%)	4 (30.8%)
	Yes	15 (36.6%)	8 (50%)	6 (46.2%)
	Unknown	26 (63.4%)	0 (0%)	3 (23%)
Tobacco Use	*No*	13 (31.7%)	4 (25%)	5 (38.5%)
	Yes	27 (65.9%)	12 (75%)	8 (61.5%)
	Unknown	1 (2.4%)	0 (0%)	0 (0%)